

Supplementary Table 1. Two different treatment regimens for anti-vascular endothelial growth factor therapy in patients with diabetic macular edema.

PRN regimen (BCVA and OCT examined at every clinic visit)	
Injection	Follow-up only
<ul style="list-style-type: none"> ● BCVA loss \geq 5 ETDRS letters OR ● New or increased SRF and/or IRC OR ● CFT increase \geq 100 μm 	<ul style="list-style-type: none"> ● BCVA loss $<$ 5 ETDRS letters AND ● No SRF and IRC, or stable IRC over 2 consecutive treatment visits after the loading phase AND ● CFT increase $<$ 100 μm
T&E regimen (BCVA and OCT examined at every clinic visit)	
Shorten (- 4 weeks) Minimum interval: 4 weeks	Extend (+ 4 weeks) Maximum interval: 24 weeks
<ul style="list-style-type: none"> ● BCVA loss \geq 5 ETDRS letters OR ● New or increased SRF and/or IRC OR ● CFT increase \geq 100 μm 	<ul style="list-style-type: none"> ● BCVA loss $<$ 5 ETDRS letters AND ● No SRF and IRC, or stable IRC over 2 consecutive treatment visits after the loading phase AND ● CFT increase $<$ 100 μm

BCVA, best-corrected visual acuity; CFT, central foveal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IRC, intraretinal cyst; OCT, optical coherence tomography; PRN, pro re nata; SRF, subretinal fluid; T&E, treat-and-extend.